ClarityCut AI Launches to Revolutionize Video Editing with AI-Powered Simplicity
SEATTLE, June 02, 2025 ( GLOBE NEWSWIRE ) -- CLEANZONE HVAC LLC proudly announces the official launch of ClarityCut AI, a cutting-edge video editing platform designed to empower creators through the speed and precision of artificial intelligence.
GFG Announces Encouraging Phase 1 Drill Results from Pen Gold Project, Ontario
Gold and base metals mineralization intersected at multiple targets. exploration budget increased to support aggressive H2 program Gold and base metals mineralization intersected at multiple targets. exploration budget increased to support aggressive H2 program ...
Stomp Into Some Prehistoric Learning! Lingokids and BBC Earth Launch New Walking With Dinosaurs Lesson to Bring a Love of Dinosaurs to a New Generation
LOS ANGELES, June 02, 2025 ( GLOBE NEWSWIRE ) -- Get ready to dig, discover, and roar with excitement.
Should You Buy Lucid While It's Below $3?
Lucid Group ( NASDAQ: LCID ) makes some of the best-looking electric vehicles in the U.S. They've won accolades from automotive publications, and offer some of the EV world's longest battery ranges. So you might assume the EV start-up would have a rapidly rising share price to boot.
First Atlantic Nickel to Attend Benchmark Mineral Intelligence's GIGA USA 2025 Conference, Highlighting Atlantic Nickel Project's Smelter-Free Processing for North America's Critical Minerals Supply Chain
First Atlantic to engage with industry leaders, automakers, battery manufacturers, and government stakeholders at GIGA USA 2025 Conference, June ...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - Vera Therapeutics ( NASDAQ:VERA )
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria ( UPCR ) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 ( p<0.0001 )
Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company for $4.65 Million as Part of Company Streamlining
Proceeds to Support Company's Strategic Focus on Data Center Business Proceeds to Support Company's Strategic Focus on Data Center Business ...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy ( IgAN ) in adults.
Liquidia Schedules First Commercial Shipment of YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with PAH and PH-ILD - Liquidia ( NASDAQ:LQDA )
YUTREPIA now available to be prescribed to patients via specialty pharmacies Court denies United Therapeutics' request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch
